The FDA granted accelerated approval to camizestrant, an oral SERD from AstraZeneca, for ER+ breast cancer based on results from the Phase 3 SERENA-6 study. The approval follows Phase 2 efficacy data and is designed around detecting ESR1 mutations earlier through ctDNA “molecular progression” rather than waiting for imaging-based clinical progression. SERENA-6 evaluated whether earlier adaptation to resistance mechanisms improves outcomes and quality of life compared with standard of care. The program underscores a growing regulatory willingness to incorporate liquid-biopsy-driven endpoints for treatment adaptation decisions in oncology. The accelerated approval also adds momentum for oral SERD strategies competing in ER+ disease, particularly as the class faces patent expiration pressures across the broader oncology market.